Amanda Hernandez, MD, PhD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    Genentech
    Topic:
    Neuroimmunology
    Date added:
    12/08/2025
    Date updated:
    12/08/2025
    Relationship end date:
    07/01/2026
  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    Amgen
    Topic:
    Neuroimmunology
    Date added:
    12/08/2025
    Date updated:
    12/08/2025
    Relationship end date:
    07/01/2026
  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    Alexion
    Topic:
    Neuroimmunology
    Date added:
    12/08/2025
    Date updated:
    12/08/2025
    Relationship end date:
    07/01/2026
  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    Argenx
    Topic:
    Neuroimmunology
    Date added:
    12/08/2025
    Date updated:
    12/08/2025
    Relationship end date:
    07/01/2026
  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    UCB
    Topic:
    Neuroimmunology
    Date added:
    12/08/2025
    Date updated:
    12/08/2025
    Relationship end date:
    07/01/2026
  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    Johnson & Johnson
    Topic:
    Neuroimmunology
    Date added:
    12/08/2025
    Date updated:
    12/08/2025
    Relationship end date:
    07/01/2026
  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    EMD Serono
    Topic:
    Neuroimmunology
    Date added:
    12/08/2025
    Date updated:
    12/08/2025
    Relationship end date:
    07/01/2026
Return to 12/11/2025: Statin-induced Immune-mediated Necrotizing Myopathy, Jesenia Isaza, MD,